11 known cases. View patent page →
Antitrust/pay-for-delay litigation challenging Revlimid generic settlements. Patents cited include the Revlimid patent family; on September 29, 2026, the court denied motions to dismiss, finding a plausible pay-for-delay agreement between Celgene and Natco.
Antitrust action against Celgene concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.
Antitrust action by Blue Cross Blue Shield Association plaintiffs against Celgene/BMS concerning Revlimid settlements; patents cited include the same Revlimid patent set as the In re Revlimid litigation.
Antitrust action against Celgene; patents listed: 8,288,415; 8,315,886; 8,404,717. Assigned to Judge Esther Salas and Magistrate Michael A. Hammer. No termination date listed as of Feb. 19, 2026.
Celgene brought this ANDA patent-infringement suit against Natco, Arrow, and Watson. The '717 patent was added by Fifth Amended Complaint on May 6, 2013, and the case settled on December 22, 2015, with a license to market generic lenalidomide beginning January 31, 2026; the docket terminated January 5, 2016.
Celgene sued Dr. Reddy's Laboratories entities, asserting the '717 patent among 16 patents. The case was resolved by settlement via a Celgene–Dr. Reddy's volume-limited license agreement reported in 2020.
Celgene sued Lotus and Alvogen, asserting the '717 patent among 16 patents. A consent judgment/injunction was entered on March 29, 2019, enjoining Lotus/Alvogen until expiration of the patents-in-suit, including the '717 patent.
Celgene asserted the '717 patent, along with other patents, against Hetero Labs Ltd. et al. The case was settled or otherwise resolved as part of the serial sham-litigation settlements alleged in the antitrust MDL; the exact civil-action number was not confirmed.
Celgene asserted the '717 patent, along with other patents, against Cipla. The case was settled; the exact case number was not confirmed.
Dr. Reddy's filed an inter partes review challenging the '717 patent. The PTAB denied institution on the merits by decision dated February 11, 2019; refund notices were filed in 2019.
Listed on the Google Patents 'Family has litigation' panel for US 8,404,717; the narrative could not confirm party names or outcome.